Stock Insider Trading (from SEC Form 4)

RDUS / Radius Health, Inc. insiders include Fitzpatrick Lorraine A. (Chief Medical Officer), BIOTECH GROWTH N V, and MPM Bio IV NVS Strategic Fund LP, MPM BioVentures IV LLC, MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC, MPM BIOVENTURES III GP L.P., Ward Robert (President & CEO), Foley Todd, STEINMETZ MICHAEL, GADICKE ANSBERT, GALAKATOS NICHOLAS, Carmona Jose (Chief Financial Officer), Hattersley Gary (Chief Scientific Officer), Hatzis-Schoch Brent (Sr. VP, General Counsel), KAILIAN VAUGHN M, MPM BIOVENTURES III L.P., EVNIN LUKE, MPM BIOVENTURES III GMBH & CO. Beteiligungs KG, MPM BIOVENTURES III-QP L.P., MPM BIOVENTURES III PARALLEL FUND, L.P., Scopa James Paul, Purandare Dinesh (SVP Global Oncology/Commercial), MPM BIOVENTURES III LLC, SIMON NICHOLAS J III, MPM BioVentures IV GP LLC, HENNER DENNIS, Hoiland Jesper (President and CEO), BB BIOTECH AG Harvey Brian Nicholas (Sr. VP and CFO), Snow David P. (Chief Commercial Officer), Graves Kurt, WHEELER KURT, .


Radius Health, Inc. insider trades are found here. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

Job titles are listed as of the filing and may not be current. Click the link icon to see the full transaction history.

Latest
File Date
Latest
Tran Date
Insider Code Shares Post Shares Percent
Change
Share
Price
Tran Value Post Value Percent
Change
2017-11-16 2017-11-14 BIOTECH GROWTH N V 10% Owner
BB BIOTECH AG 10% Owner
P 50,000 5,698,799 0.89 26.2478 1,312,390 149,580,936 0.88
2017-11-13 2017-11-10 Hatzis-Schoch Brent Sr. VP, General Counsel
P 1,778 2,278 355.60 28.0893 49,943 63,987 78.05
2017-11-07 2017-11-07 Hoiland Jesper President and CEO, Director
P 6,800 12,900 111.48 29.0368 197,450 374,575 52.71
2017-09-15 2017-09-14 Carmona Jose Chief Financial Officer
P 3,000 3,000 32.8343 98,503 98,503 100.00
2017-04-27 2017-04-25 Harvey Brian Nicholas Sr. VP and CFO
M 39,616 76,189 108.32 2.74 108,548
2016-10-25 2016-10-25 Ward Robert President & CEO, Director
M 10,000 15,000 200.00 7.8 78,000
2016-09-29 2016-09-27 MPM BioVentures IV LLC
Scopa James Paul
MPM BioVentures IV GP LLC
MPM Bio IV NVS Strategic Fund LP
KAILIAN VAUGHN M
Foley Todd
J -713,849 1,427,698 -33.33
2016-09-29 2016-09-27 EVNIN LUKE
J -1,943,751 3,887,502 -33.33
2016-09-29 2016-09-27 GADICKE ANSBERT Director
J -1,943,751 3,887,502 -33.33
2016-09-29 2016-09-27 GALAKATOS NICHOLAS
SIMON NICHOLAS J III
WHEELER KURT
J -1,229,902 2,459,804 -33.33
2016-09-29 2016-09-27 MPM BIOVENTURES III LLC
HENNER DENNIS
MPM ASSET MANAGEMENT INVESTORS 2003 BVIII LLC
MPM BIOVENTURES III GMBH & CO. Beteiligungs KG
MPM BIOVENTURES III PARALLEL FUND, L.P.
MPM BIOVENTURES III GP L.P.
MPM BIOVENTURES III L.P.
MPM BIOVENTURES III-QP L.P.
STEINMETZ MICHAEL
J -1,229,902 2,459,804 -33.33
2016-01-26 2016-01-25 Fitzpatrick Lorraine A. Chief Medical Officer
P 100 200 100.00 37.97 3,797 7,594 50.00
2015-11-13 2015-11-12 Hattersley Gary Chief Scientific Officer
S -5,683 0 -100.00 75.00 -426,225
2015-09-28 2015-09-14 Snow David P. Chief Commercial Officer
P 6,000 6,000 69.79 418,740 418,740 100.00
2015-09-08 2015-08-31 Purandare Dinesh SVP Global Oncology/Commercial
P 200 200 62.20 12,440 12,440 100.00
2015-08-19 2015-08-17 Graves Kurt Director
S -22,694 0 -100.00 70.00 -1,588,580
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related News Stories

Biotech Stocks Near Massive Breakout | Investopedia

2018-01-15 investopedia
(Note: The author of this fundamental analysis is a financial writer and portfolio manager. He and his clients own shares of ALKS.) (148-1)

Weekly Insider Trading

2017-12-28 seekingalpha
It is Christmas time and some extra time to... work! My pilot article ("Weekly Insider Trading") was published as recently as December 23, but it covered four biotech and IT companies with the most interesting insider trading dating back 3 months. This article follows my standard work and investing process by looking back at the last week’s most interesting transactions. (291-2)

Weekly Insider Trading

2017-12-23 seekingalpha
Radius Health: Well capitalized, has seen consistent insider activity from major owners as well as officers, and looks interesting from a technical chart perspective. (39-2)

E*TRADE Rallies 14.2% Quarter to Date: Is More Upside Left?

2017-12-19 zacks
Improving operating backdrop, rising rate environment, expectations of lesser regulations, lower tax rates and strengthening domestic economy have driven investors’ optimism on banking stocks. Therefore, some of these stocks are profitable picks, due to strong fundamentals and solid long-term prospects. One such investment bank — E*TRADE Financial Corporation (ETFC - Free Report) — has rallied 14.2% quarter to date, significantly outperforming the industry’s gain of 11. (44-0)

McDermott Inks $6B Merger Deal With Chicago Bridge & Iron

2017-12-19 zacks
In a bid to create a fully-vertically integrated company, McDermott International, Inc. (MDR - Free Report) is set to merge with Chicago Bridge & Iron Company N.V. (CBI - Free Report) in a $6 billion all-stock deal.  (39-0)

Add These 4 GARP Stocks to Your Portfolio for Better Returns

2017-12-19 zacks
Growth at a reasonable price or GARP is an excellent way for investors to make some quick gains. This strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. The GARP approach leads to the identification of stocks that are priced below the market or any reasonable target determined by fundamental analysis. These stocks also have solid prospects in terms of cash flow, revenues, earnings per share (EPS) and so on. (50-0)

Quest Diagnostics, LabCorp Defend Lab Fee Suit Against HHS

2017-12-19 zacks
Healthcare diagnostic majors and arch-rivals Quest Diagnostics Incorporated (DGX - Free Report) and Laboratory Corporation of America Holdings (LH - Free Report) or LabCorp are on the same page regarding the much contentious topic of Protecting Access to Medicare Act (“PAMA”) on clinical lab fee schedule.  Recently, both the companies as members of the American Clinical Laboratory Association (“ACLA”) have come forward to support a lawsuit filed by ACLA against the Acting Secretary of the U. (34-0)

4 Reasons to Invest in DNB Financial (DNBF) Stock Right Now

2017-12-19 zacks
Underlying strength and earnings growth prospects make DNB Financial Corporation (DNBF - Free Report) a solid bet now. The company’s organic growth strategies have positioned it well for growth. Also, improving operating backdrop, a rising rate environment and expectations of lesser regulations and lower tax rates are likely to further support profitability. Analysts seem to be optimistic about the company’s prospects as the stock has been witnessing upward estimate revisions. (47-0)

Here's Why You Should Hold UDR Stock in Your Portfolio Now

2017-12-19 zacks
UDR, Inc. (UDR - Free Report) has been continuously enhancing the overall quality of its portfolio by acquiring, developing and redeveloping properties in core operating markets and divesting non-core assets. While the company’s extensive portfolio-repositioning activities will aid its prospects, increase in supply of residential units will likely result in lesser absorption. (35-0)

Hershey to Buy SkinnyPop Owner Amplify for $1.6 Billion

2017-12-19 zacks
In a bid to go beyond chocolate and gain a solid footing in the fast-growing market for healthy snacks Hershey Co. (HSY - Free Report) inked a deal to acquire Amplify Snack Brands Inc. (BETR - Free Report) — the maker of SkinnyPop and Tyrrell’s potato chips. Consequently, Amplify's shares were up 71.6% on Dec 18 while Hershey gained a mere 0.1%. Terms of the Deal Hershey agreed to buy all outstanding shares of Amplify Snack Brands for $12 a share, which is a 71% premium to Friday’s closing price. (48-0)